Trial Search Results

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3 to 9 hours from onset of stroke symptoms.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

H. Lundbeck A/S


  • Drug: Desmoteplase
  • Drug: Placebo


Phase 3


Inclusion Criteria:

   - Diagnosis of acute ischemic stroke

   - Informed consent

   - Age between 18 and 85 years

   - Treatment can be initiated within 3 to 9 hours after the onset of stroke symptoms

   - NIHSS Score of 4 to 24

   - Vessel occlusion or high-grade stenosis on MRI or CTA in proximal cerebral arteries

Exclusion Criteria:

   - Pre-stroke mRS >1

   - Previous exposure to desmoteplase

   - Extensive early infarction on MRI or CT in any affected area

   - Imaging evidence of ICH or SAH; AV malformation; cerebral aneurysm; or cerebral

   - Internal carotid artery occlusion on the side of the stroke lesion

   - Treatment with heparin in the past 48 hours and a prolonged partial thromboplastin

   - Treatment with oral anticoagulants and a prolonged prothrombin time

   - Treatment with glycoprotein IIb - IIIa inhibitors within the past 72 hours. Use of
   single agent oral platelet inhibitors is permitted

   - Treatment with a thrombolytic agent within the past 72 hours

Ages Eligible for Study

18 Years - 85 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maarten Lansberg
Not Recruiting